Takeda halts TAK-994 narcolepsy treatment development due to hepatotoxicity concerns

Takeda's pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an abrupt halt due to hepatotoxicity concerns, according ... Read More